Supplementary Table 9 from A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial
Authors:
- Josep TaberneroJTJosep Tabernero
- Takayuki YoshinoTYTakayuki Yoshino
- Sebastian StintzingSSSebastian Stintzing
- Aimery de GramontAGAimery de Gramont
- Peter GibbsPGPeter Gibbs
- Derek J. JonkerDJDerek J. Jonker
- Peter NygrenPNPeter Nygren
- Christos PapadimitriouCPChristos Papadimitriou
- Gerald W. PragerGPGerald W. Prager
- Roger TellRTRoger Tell
- Heinz-Josef LenzHLHeinz-Josef Lenz
Open Access
- 4 January 2024
- other
- Published by American Association for Cancer Research (AACR)